See more : Resorttrust, Inc. (4681.T) Income Statement Analysis – Financial Results
Complete financial analysis of Alvotech (ALVO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alvotech, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Kalera Public Limited Company (KALRQ) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMFO) Income Statement Analysis – Financial Results
- Hive 2040 R&D Limited Partnership (HIVE.TA) Income Statement Analysis – Financial Results
- Kiattana Transport Public Company Limited (KIAT.BK) Income Statement Analysis – Financial Results
- Shengfeng Development Limited (SFWL) Income Statement Analysis – Financial Results
Alvotech (ALVO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.alvotech.com
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 91.43M | 83.03M | 36.77M | 66.62M | 31.92M |
| Cost of Revenue | 160.86M | 64.10M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -69.42M | 18.93M | 36.77M | 66.62M | 31.92M |
| Gross Profit Ratio | -75.93% | 22.80% | 100.00% | 100.00% | 100.00% |
| Research & Development | 210.83M | 180.62M | 191.01M | 148.07M | 95.56M |
| General & Administrative | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 76.56M | 186.74M | 84.13M | 58.91M | 48.57M |
| Other Expenses | -1.95M | -1.99M | -2.91M | -2.83M | -50.76M |
| Operating Expenses | 285.44M | 365.38M | 272.23M | 204.15M | 93.37M |
| Cost & Expenses | 446.46M | 429.47M | 272.23M | 204.15M | 93.37M |
| Interest Income | 4.82M | 2.55M | 51.57M | 215.00K | 1.74M |
| Interest Expense | 134.82M | 188.42M | 117.36M | 97.47M | 95.76M |
| Depreciation & Amortization | 24.21M | 20.41M | 18.20M | 16.42M | 14.61M |
| EBITDA | -484.86M | -439.80M | 3.99M | -125.67M | -99.02M |
| EBITDA Ratio | -530.29% | -392.72% | -457.17% | -188.65% | -150.74% |
| Operating Income | -354.86M | -346.44M | -235.46M | -137.54M | -61.45M |
| Operating Income Ratio | -388.11% | -417.25% | -640.31% | -206.46% | -192.52% |
| Total Other Income/Expenses | -296.19M | -205.21M | 86.26M | -154.23M | -147.94M |
| Income Before Tax | -651.05M | -551.65M | -149.20M | -291.77M | -209.39M |
| Income Before Tax Ratio | -712.04% | -664.40% | -405.74% | -437.99% | -656.01% |
| Income Tax Expense | -99.32M | -38.07M | -47.69M | -121.73M | 491.00K |
| Net Income | -551.73M | -513.58M | -101.50M | -170.04M | -209.88M |
| Net Income Ratio | -603.42% | -618.55% | -276.04% | -255.26% | -657.55% |
| EPS | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| EPS Diluted | -2.43 | -2.60 | -3.25 | -5.44 | -0.86 |
| Weighted Avg Shares Out | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
| Weighted Avg Shares Out (Dil) | 227.26M | 197.72M | 31.25M | 31.25M | 243.65M |
Alvotech (ALVO) Q2 2024 Earnings Call Transcript
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe
Alvotech Announces Closing of Private Debt Financing
Source: https://incomestatements.info
Category: Stock Reports